Midwest Financial Partners Investments Inc. Takes Position in Illumina, Inc. $ILMN

Midwest Financial Partners Investments Inc. acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the 4th quarter, Holdings Channel.com reports. The firm acquired 3,662 shares of the life sciences company’s stock, valued at approximately $480,000.

Several other institutional investors have also modified their holdings of the business. Elyxium Wealth LLC acquired a new position in Illumina in the 4th quarter worth $25,000. Creative Capital Management Investments LLC boosted its stake in Illumina by 160.0% in the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after purchasing an additional 120 shares during the period. Board of the Pension Protection Fund acquired a new position in Illumina in the 4th quarter worth $26,000. TD Waterhouse Canada Inc. acquired a new position in Illumina in the 4th quarter worth $26,000. Finally, Laurel Wealth Advisors LLC acquired a new position in Illumina in the 4th quarter worth $26,000. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

ILMN opened at $144.83 on Friday. Illumina, Inc. has a 52-week low of $78.55 and a 52-week high of $155.53. The firm has a market capitalization of $21.91 billion, a PE ratio of 26.33, a PEG ratio of 2.35 and a beta of 1.42. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. The business’s 50-day simple moving average is $129.99 and its 200 day simple moving average is $130.81.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The business had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the prior year, the company posted $0.97 earnings per share. Illumina’s revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, sell-side analysts expect that Illumina, Inc. will post 5.2 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Guggenheim upped their target price on shares of Illumina from $144.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. JPMorgan Chase & Co. upped their target price on shares of Illumina from $120.00 to $125.00 and gave the stock a “neutral” rating in a research note on Friday, May 1st. Evercore reaffirmed an “outperform” rating on shares of Illumina in a research note on Friday, May 1st. Wall Street Zen cut shares of Illumina from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Finally, UBS Group reaffirmed a “neutral” rating and set a $135.00 price target on shares of Illumina in a research note on Friday, February 6th. Seven equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Illumina has an average rating of “Hold” and an average target price of $137.75.

Insider Activity

In related news, SVP Christensen Jakob Wedel sold 700 shares of the company’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total transaction of $97,328.00. Following the sale, the senior vice president owned 15,056 shares in the company, valued at approximately $2,093,386.24. This represents a 4.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 104,393 shares of the stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $145.34, for a total transaction of $15,172,478.62. Following the completion of the sale, the director owned 3,500,048 shares of the company’s stock, valued at approximately $508,696,976.32. This represents a 2.90% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 330,160 shares of company stock worth $48,028,308 in the last quarter. 2.90% of the stock is currently owned by corporate insiders.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.